Object. Patients with aneurysmal subarachnoid hemorrhage (SAH) are at high risk for delayed cerebral ischemia (DCI) and stroke. Epoxyeicosatrienoic acids (EETs) play an important role in cerebral blood flow regulation and neuroprotection after brain injury. Polymorphisms in the gene for the enzyme soluble epoxide hydrolase (sEH), which inactivates EETs, are associated with ischemic stroke risk and neuronal survival after ischemia. This prospective observational study of patients with SAH compares vital and neurologic outcomes based on functional polymorphisms of sEH.
Methods. Allelic discrimination based on quantitative real-time polymerase chain reaction was used to differentiate wild-type sEH from K55R heterozygotes (predictive of increased sEH activity and reduced EETs) and R287Q heterozygotes (predictive of decreased sEH activity and increased EETs). The primary outcome was new stroke after SAH. Secondary outcomes were death, Glasgow Outcome Scale score, and neurological deterioration attributable to DCI.
Results. Multivariable logistic regression models adjusted for age at admission and Glasgow Coma Scale scores revealed an increase in the odds of new stroke (OR 5.48 18 .52]) in patients with R287Q genotype, compared with wild-type sEH. The R287Q genotype was associated with reduced odds of having a Glasgow Outcome Scale score of ≤ 3 (OR 0.23 [95% CI 0.06-0.82]). There were no significant differences in the odds of neurological deterioration due to DCI.
Conclusions. Genetic polymorphisms of sEH are associated with neurological and vital outcomes after aneurysmal SAH.
(http://thejns.org/doi/abs /10.3171/2014.7.JNS131990) have been identified, for which population studies have reported frequencies up to 20% for the most common polymorphisms.
8 One variant, known as K55R, confers increased sEH activity and inactivation of EETs, and has been linked to hypertension, ischemic stroke, and coronary artery disease. 5, 9, 18 Another form, R287Q, results in reduced sEH activity and potentially higher EET levels. This variant has been associated with equivocal ischemic stroke risk, but enhanced neuronal survival after ischemic injury in vitro. 9, 15, 31 It is unknown how genetic variation in sEH is associated with the risk of DCI, stroke, or death in patients with SAH. In the present study we compare 2 common genetic variants to wild-type (WT) sEH and determine the association between sEH variants and outcome in patients with SAH.
Methods

Patient Population
Adult patients with aneurysmal SAH confirmed on cerebral angiography between December 1, 2008, and November 1, 2013, were recruited from the Neurosciences intensive care unit (ICU) at Oregon Health & Science University, a 572-bed stroke referral center in Portland, Oregon. Patients were excluded if they were pregnant, had nonaneurysmal or spontaneous SAH, or had severe preexisting neurological or cardiac disease. Patients who died in the first 72 hours of their ICU stay were not enrolled. The study was approved by the institutional review board and informed consent was obtained. Patients were comanaged by neurosurgeons and neurointensivists based on established guidelines for the management of SAH.
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Genotyping Analysis
We selected 2 of the most common EPHX2 polymorphisms (K55R and R287Q) for analysis based on prevalence reported in previous studies, a documented effect on sEH enzyme activity, and previous associations with disease states. 5, 18, 31 Blood samples were collected at the time of informed consent. The DNA was extracted and purified from peripheral leukocytes by using the QIAamp DNA Micro Kit (Qiagen) protocol. Allelic discrimination of EPHX2 was performed by TaqMan amplification (Applied Biosystems) using a PRISM 7000 sequence detection system (Applied Biosystems). Following quantitative polymerase chain reaction (qPCR) allelic discrimination, 10% of the DNA samples were sequenced for verification of process integrity and quality control. All sequenced samples corresponded to specific alleles found with the qPCR allelic discrimination method.
Data Collection
Baseline demographic and physiological data were retrieved from electronic medical records. The Simplified Acute Physiology Score (SAPS II) was calculated from the worst laboratory values in the first 24 hours following admission. 17 Stress cardiomyopathy was defined as wall motion abnormalities in a nonvascular distribution diagnosed on 2D echocardiography with a documented resolution during the hospital course. 13 Neurogenic fever was defined as a body temperature > 38.3°C documented on at least one measurement during the first 72 hours of the hospital stay, without documented infection. 21 Development of acute respiratory distress syndrome (ARDS), cerebral salt wasting (CSW), or syndrome of inappropriate secretion of antidiuretic hormone (SIADH) was determined from diagnoses in progress notes and was not based on direct evaluation of objective data.
Transcranial Doppler (TCD) and angiographic vasospasm data are reported as positive if maximum middle cerebral artery velocity on TCD was ≥ 200 ml/sec and/or the Lindegaard ratio was > 3.0, and as any degree of blood vessel narrowing identified on the angiogram report, respectively. 19 Interventional angiography was defined as either administration of intraarterial verapamil at any dose, or (rarely) as balloon angioplasty.
Patient Outcomes
Based on recent multicenter consensus guidelines for outcome studies after SAH, the primary outcome of interest was "new stroke attributable to DCI." 30 A new stroke was defined as a cerebral infarction identified on hospital discharge or follow-up that was not present on imaging between 24 and 48 hours after aneurysm occlusion, and that was not attributable to other causes such as surgical clipping or endovascular treatment. Hypodensities resulting from extraventricular drains (EVDs) or residual intraparencyhmal hematomas were excluded.
Secondary outcomes included death, functional status at discharge, and the development of an acute neurological deterioration attributable to DCI. Hospital deaths was inclusive of patients for whom care was withdrawn. Functional outcome was determined based on the Glasgow Outcome Scale (GOS) at hospital discharge or 6-week follow-up, whichever was later. Neurological deterioration was defined as the development of focal neurological signs or decreased level of consciousness that resulted in a decrease in the Glasgow Coma Scale (GCS) score of 2 points, lasting at least 1 hour, and not attributable to infection, changes in sedation, or nonischemic cerebral pathology such as acute hydrocephalus.
To detect the possibility that patients with high-grade SAH would have a poor outcome regardless of genotype, we did a sensitivity analysis excluding patients with Hunt and Hess Grade IV and V.
Statistical Analysis
Patients with SAH were separated into groups based on EPHX2 genotypes. One-way ANOVA was used to detect differences between groups for continuous variables. Kruskal-Wallis ANOVA by ranks was used to detect differences between groups for nonparametric distributions of data. To allow for unequal sample size between groups, the Tukey-Kramer post hoc pairwise comparison test was used to assess for significance at a level of a = 0.025. Associations between categorical variables were investigated using the chi-square statistic. Categorical variables are presented as frequency distributions, and continuous variables are expressed as either the mean ± SD or medians (interquartile range [IQR]), depending on distribution.
Unadjusted regression models that included only the main predictor of interest were fitted to estimate the association between EPHX2 genotype and outcomes. The models were then tested for fit with a priori selected confounding factors. Admission GCS, SAPS II, Fisher grade, and Hunt and Hess scores were highly collinear. The SAPS II, troponin, and mechanical ventilation data did not contribute to the model, whereas GCS score and age improved the fit of the model. The adjusted models included the genotype, age, and admission GCS score.
To assess the significance of differences in outcomes across groups, and as a surrogate for a post hoc power analysis, we performed an analysis of the minimum effect size detectable between groups for the primary outcome. All p values are 2-sided, with a 0.05 level of significance. A commercially available statistical program was used for all analyses (STATA version 12.0; StataCorp). The PASS version 12 (NCSS, LLC) was used to calculate minimum effect size.
Results
Study Population
During the study period, 95 patients with a diagnosis of aneurysmal SAH met the inclusion criteria and gave informed consent. Of those, 57 (60.0%) had WT sEH, 14 (14.7%) were K55R heterozygous, 23 (24.2%) were R287Q heterozygous, and 1 (1.1%) was R287Q homozygous. The R287Q genotypes were combined for analysis (25.3%).
Demographic and Physiological Data
Demographic and baseline physiological characteristics of the study population are shown in Table 1 . No significant differences were noted with respect to age, sex, weight, distribution and severity of SAH, or neurological presentation at admission. Among the K55R group, 100% were Caucasian compared with 82.4% in the WT group and 58.3% in the R287Q group (p = 0.006). Groups were similar in mean SAPS II scores at admission, incidence of EVD placement, and prior anticoagulation. Similar proportions of patients had aneurysms treated with surgical clipping and endovascular coil insertion. There was a trend toward an increased peripheral white blood cell (WBC) count in the K55R group, but this did not reach statistical significance.
A summary of ICU complications and interventions stratified by EPHX2 genotype is shown in Table 2 . No significant differences in the frequency of ICU interventions or drug therapy were noted between the groups. No differences were noted in the incidence of stress-induced cardiomyopathy, neurogenic fever, or CSW or SIADH. Significantly more patients with the K55R genotype developed ARDS when compared with the other genotypes (p = 0.012). There were no differences in the cumulative 7-day fluid balance between the groups. Neurological Outcome. No significant differences were noted in the incidence of TCD or angiographic vasospasm, or in the use of angiographic interventions for vasospasm between the groups (Table 3) . Patients in the K55R group had significantly worse GCS scores on ICU discharge when compared with patients in the WT group (post hoc test; p = 0.025). In the K55R genotype group, 71.4% had a GOS score of ≤ 3 at hospital discharge or follow-up, compared with 64.9% in the WT group and 37.5% in the R287Q group (p = 0.043; post hoc WT vs R287Q, p = 0.023). There was no difference in the incidence of clinical neurological deterioration attributable to DCI. Patients with R287Q genotype sEH had significantly decreased hospital length of stay (p = 0.009) compared with WT. There were no significant differences in disposition location based on genotypes.
Study End Points
The odds of developing a neurological deterioration attributable to DCI were unchanged with either genotype when compared with WT sEH, even after adjustment for potential confounders at admission ( Table 4 ). The odds of a discharge GOS score of ≤ 3 were significantly reduced in patients with R287Q genotype (OR 0.32 [95% CI 0.12-0.87]), an association that was maintained after adjustment for potential confounders (OR adj 0.23 [95% CI 0.06-0.82]). When patients with Hunt and Hess scores of IV and V were excluded, the results were similar.
Effect Size
The minimum detectable effect size of genotypes on the primary outcome (new stroke) was a 32.3% increase in the risk of stroke attributable to DCI.
Discussion
We report important differences in outcome of patients with aneurysmal SAH based on genetic polymorphisms of sEH. A polymorphism predictive of increased sEH activity compared with WT (K55R) was associated with increased odds of new ischemic stroke, and increased odds of death, without a change in the odds of poor functional status at discharge or neurological deterioration during the ICU stay. A polymorphism predictive of decreased activity (R287Q) was associated with decreased odds of a poor functional outcome, but there was no difference in the odds of new stroke or death compared with WT.
Increased Metabolism of EETs and Outcomes After SAH
The K55R genotype sEH was associated with increased odds of stroke and death. Outcome after SAH in patients with K55R sEH may be worse due to enhanced metabolism and inactivation of EETs; the K55R genotype sEH has been previously shown to metabolize EETs more efficiently than WT sEH. 18 The EETs play an important role in CBF regulation and protection from ischemic injury, and reduced levels have been associated with vascular dysfunction and stroke.
11 Interestingly, we detected differences in new stroke and death, but these are not explained by differences in the incidence of neurological deteriorations or vasospasm between K55R and WT sEH.
One possible explanation for this finding is that it is often challenging to detect DCI in critically ill, brain-injured patients until a stroke has already occurred. Another explanation is that in addition to having potent vasoactive properties, EETs are antiinflammatory, promote angiogenesis and axonal regeneration, and inhibit platelet aggregation. 1, 6, 7, 11, 14, 16 It is possible that abnormalities in CBF or metabolism as a result of microthrombosis, inflammation, and impaired neurovascular coupling are more prevalent in patients with the K55R genotype, and that these abnormalities influence the risk of stroke without detectable, acute neurological changes or vasospasm. To support this hypothesis we also found a significantly larger subgroup of patients with the K55R genotype who presented with admission WBC > 20,000/ml. (Leukocytosis has also previously been independently associated with * Data are expressed as the mean ± SD unless otherwise specified. ACA = anterior cerebral artery; ACoA = anterior communicating artery; ICA = internal carotid artery; MAP = mean arterial pressure; MCA = middle cerebral artery; PCA = posterior cerebral artery; PCoA = posterior communicating artery.
DCI after SAH.) 12 We also report a significant increase in the incidence of ARDS in patients with K55R genotype sEH, which provides additional evidence that inflammatory changes modulated by EETs may be important in the development of DCI and poor outcome.
A Protective Role for EETs?
Patients with the R287Q genotype sEH had decreased odds of a poor functional neurological outcome without changes in the odds of stroke or death. There were no differences in the incidence of acute neurological deteriora- tion or vasospasm. Perhaps more durable EET signaling and beneficial microvascular regulation of blood flow influence longer-term neurological function in these patients. One study has shown that R287Q sEH is associated with improved neuronal survival after ischemic conditions in vitro. 15 Population studies have also shown equivocal risk of developing an ischemic stroke with R287Q genotype sEH.
9, 31 We demonstrate an improved neurological outcome, but no other indicators of benefit. An alternative explanation is that although decreased levels of EETs are somehow harmful, increased EET levels are not necessarily beneficial. It is possible that less sEH activity merely shifts EET metabolism to other, nonenzymatic pathways.
Our findings support an association between sEH activity and outcome after SAH, and contribute to a growing body of literature that suggests a role for manipulation of sEH activity in the secondary prevention of complications after brain injury. 10 Inhibitors of sEH are biologically active with respect to the regulation of vascular tone, hyperglycemia, and reduction of inflammatory response to insults.
2 In experimental stroke in animal models, sEH inhibitors decrease infarct size without increasing measured CBF when compared with untreated animals.
33
These findings could partially explain the differences in outcome we observed, without differences in vasospasm or acute neurological deterioration.
Selection of Outcomes
The goal of this study was to identify clinical outcomes related to delayed ischemia that may be influenced by EETs and sEH genetic polymorphisms. Translating observational physiological variables into a summary definition of DCI, however, can be challenging and imprecise, especially given that EETs have many potential roles. We chose to identify new stroke as the primary outcome and death as a secondary outcome because they are the most objectively quantifiable, and this decision was based on the recommendations of a multicenter consensus statement for the study of DCI after SAH. 30 These outcomes do not provide a precise explanation of causality. Delayed cerebral ischemia has a broad pathogenesis, including neurovascular uncoupling, cortical spreading depression, microthrombosis, microvascular spasm, and large-vessel vasospasm.
4,27-29 These pathological disturbances are sometimes undetectable with standard monitoring until an infarction has occurred. For more sensitive detection of episodes of ischemia that may not have resulted in infarction, we selected acute neurological deterioration in the ICU and functional neurological status at discharge as secondary outcomes. However, many nonischemic processes (such as hydrocephalus, fever, and electrolyte abnormalities) can result in neurological changes, and a change in examination results can be imperceptible in patients who are intubated, sedated, or have poor examination findings at baseline. We also included objective measures of vasospasm, considering that it is an important, albeit incomplete, contributor to DCI.
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Other Limitations
There are several limitations in the data presented. As a measure of neurological function, the GOS is imprecise. The data we present were collected at hospital discharge, due to different follow-up intervals and a proportion of patients lost to follow-up, which could have influenced the results. Many patients' discharge neurological status may not be reflective of their eventual neurological recovery, and other patients may later have died that we were unable to quantify.
We chose to report only 2 genetic polymorphisms of EPHX2 because they are the most common, and have been previously cited as biologically important. 10 There are additional polymorphisms of EPHX2 that have been associated with sEH activity, 18 and it is possible that these polymorphisms exist in our WT group and are not detected. When compared with previous population studies, the frequencies of the genotypes we report are similar: 14.7% for K55R and 25.3% for R287Q.
Perhaps most importantly, caution should be taken with interpreting the magnitude of the associations we present. There is insufficient sample size to establish precise estimates of outcome odds ratios based on genotype, as evidenced by the wide confidence intervals. Still, we do present significantly different odds of important outcomes based on sEH genotype. That these differences are significantly different despite wide confidence intervals suggests either an unrecognized Type I error or that sEH polymorphisms strongly influence outcomes after SAH. We performed a statistical estimation of effect size for the primary outcome of new stroke, which revealed that we are able to detect a 33% difference at minimum in the odds of new stroke between the K55R and WT groups.
Conclusions
We demonstrate an association between genetic sEH enzyme hyperactivity (K55R) and both new stroke and death; enzyme dysfunction (R287Q) was associated with improved neurological outcome after SAH. Although this study represents a small sample of observational data with several limitations, it supports a future examination of the role of EETs in neuroprotection after SAH. It remains to be determined how different genotypes of sEH influence in vivo EET levels after brain injury such as SAH, and whether EET levels after injury are directly associated with clinical outcomes. If maintained levels of EETs after injury are associated with improved outcome, already existing inhibitors of sEH may represent an important therapeutic intervention for the prevention and management of neurological complications after SAH.
